Pictet Asset Management Holding SA Has $49.89 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Pictet Asset Management Holding SA boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,941,271 shares of the company's stock after buying an additional 46,931 shares during the period. Pictet Asset Management Holding SA owned approximately 2.25% of IDEAYA Biosciences worth $49,891,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter worth $13,385,000. NEOS Investment Management LLC raised its position in shares of IDEAYA Biosciences by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 16,066 shares of the company's stock valued at $413,000 after acquiring an additional 1,577 shares during the period. BIT Capital GmbH boosted its stake in IDEAYA Biosciences by 85.0% during the 4th quarter. BIT Capital GmbH now owns 63,672 shares of the company's stock worth $1,636,000 after acquiring an additional 29,259 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in IDEAYA Biosciences by 244.3% during the fourth quarter. JPMorgan Chase & Co. now owns 274,693 shares of the company's stock valued at $7,060,000 after purchasing an additional 194,913 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in IDEAYA Biosciences in the fourth quarter valued at approximately $377,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Down 8.4 %

IDYA traded down $1.37 during trading hours on Thursday, hitting $14.98. 431,039 shares of the company's stock were exchanged, compared to its average volume of 875,657. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -4.54 and a beta of 0.76. IDEAYA Biosciences, Inc. has a 1-year low of $13.73 and a 1-year high of $44.42. The stock's 50-day moving average is $20.38 and its two-hundred day moving average is $25.41.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IDYA shares. Wedbush reissued an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Stephens reissued an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.